ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
8
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
3,326
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
Author(s):
EL Kwak
,
DR Camidge
,
J Clark
Publication date:
2009
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
RNA drug delivery
Data availability:
ScienceOpen disciplines:
Medicine
,
Pharmacology & Pharmaceutical medicine
Comments
Comment on this article
Sign in to comment
Similar content
3,326
Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small cell lung cancer (SNCLC) with EML4-ALK translocations
Authors:
RE; Shaw
,
DB Costa
,
AJ Iafrate
…
Pharmacokinetics (PK) of PF‐02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients
Authors:
W Tan
,
KD Wilner
,
Y Bang
…
Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): profile 1005
Authors:
JE Frampton
See all similar